Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Leases (2019 - 2023)

Ultragenyx Pharmaceutical has reported Leases over the past 5 years, most recently at $26.4 million for Q3 2023.

  • Quarterly Leases fell 8.08% to $26.4 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $26.4 million through Sep 2023, down 8.08% year-over-year, with the annual reading at $26.0 million for FY2022, 25.69% down from the prior year.
  • Leases was $26.4 million for Q3 2023 at Ultragenyx Pharmaceutical, up from $19.2 million in the prior quarter.
  • Over five years, Leases peaked at $40.5 million in Q4 2020 and troughed at $19.2 million in Q2 2023.
  • The 5-year median for Leases is $32.2 million (2019), against an average of $31.6 million.
  • Year-over-year, Leases surged 55.61% in 2020 and then tumbled 38.48% in 2023.
  • A 5-year view of Leases shows it stood at $30.3 million in 2019, then skyrocketed by 33.62% to $40.5 million in 2020, then fell by 13.79% to $34.9 million in 2021, then dropped by 25.69% to $26.0 million in 2022, then rose by 1.8% to $26.4 million in 2023.
  • Per Business Quant, the three most recent readings for RARE's Leases are $26.4 million (Q3 2023), $19.2 million (Q2 2023), and $22.9 million (Q1 2023).